Trial Profile
A Multicentre, Cohort Study to Assess the Impact on SYMptom Burden and Patient Health-related Quality of Life of Afatinib Treatment in Advanced Non-small Cell Lung Cancer in a Real World Setting in Greece
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Apr 2022
Price :
$35
*
At a glance
- Drugs Afatinib (Primary)
- Indications Carcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 01 Apr 2021 Status changed from active, no longer recruiting to completed.
- 10 Mar 2020 Status changed from recruiting to active, no longer recruiting.
- 04 Mar 2019 Planned End Date changed from 20 Oct 2020 to 26 Mar 2021.